A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (AS).
Latest Information Update: 23 Jul 2024
Price :
$35 *
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ankylosing spondylitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Pfizer
- 15 Nov 2023 Results of Post hoc analysis of pooled data from NCT01786668 and NCT03502616 trials presented at the ACR Convergence 2023.
- 03 Jun 2023 Results of pooled post hoc analysis (n=372 from studies NCT01786668 and NCT03502616) assessing the impact of BL CRP levels on tofacitinib efficacy and safety in pts with AS presented at the 24th Annual Congress of the European League Against Rheumatism
- 14 Nov 2022 Results of post hoc pooled analysis assessing relationships between work productivity, activity impairment, and patient-reported outcomes in ankylosing spondylitis patients from NCT017866683 and NCT035026162 studies, presented at the ACR Convergence 2022.